S897 Impact of GLP-1 Agonist versus Opioid Use on Esophagogastroduodenoscopy (EGD) Outcomes: A Propensity-Matched Analysis of the U.S. Collaborative Network

Mouhand F.H. Mohamed,Azizullah Beran,Osama Hamid,Khaled Elfert,Mohanad Awadalla,Indira Bhavsar-Burke,John Guardiola
DOI: https://doi.org/10.14309/01.ajg.0001032956.79643.e5
2024-10-26
The American Journal of Gastroenterology
Abstract:Opioid users often have delayed gastric emptying or esophageal dysfunction but usually do not have esophagogastroduodenoscopy (EGD) delayed or receive specific pre-procedural precautions. Users of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are advised to withhold the medication before EGD per American Society of Anesthesiologists recommendations. This may impact medication adherence and lead to procedural delays if doses are taken. Our study aims to evaluate EGD outcomes in patients treated with GLP-1 RAs compared to chronic opioids.
gastroenterology & hepatology
What problem does this paper attempt to address?